Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
Roche set to finalise $1.5bn Poseida Therapeutics takeover
Roche to complete acquisition of U.S. biopharma company Poseida
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?
POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX
Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc. - PSTX
Poseida shares triple on Tuesday, boosted by Roche collaboration
Why This Gene-Therapy Company's Stock Is Rising 228%
Shareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders
Roche to acquire US-based Poseida Therapeutics
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024
Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
Poseida Therapeutics to Present at Upcoming Investor Conferences
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement